There are countless ASX shares to choose from on the Australian share market.

So many, it can be hard to decide which ones to buy over others.

But don't worry, to narrow things down let's take a look at a couple that Bell Potter believes could be among the best to buy now.

They have been named on its Australian equities panel, which is home to its panel of favoured Australian equities that it believes offer attractive risk-adjusted returns over the long term.

Let's take a look at two top ASX 200 shares that the broker is feeling extra bullish on:

Flight Centre Travel Group Ltd (ASX: FLT)

Travel agent giant Flight Centre could be an ASX 200 share to buy according to buy according to Bell Potter.

It believes that with tariff uncertainty now in the rearview mirror, it could be a good time to buy. Especially given the low multiples its shares trade on and its expectation that Flight Centre will deliver strong earnings growth in the coming years. It said:

With peak tariff uncertainty passed, we don't think upside is being priced into FLT at ~$13. Trading at 11.2x 12MF P/E and with 18% EPS growth 2yr CAGR, we think there is potential for the stock to re-rate closer to historical average around ~14x. They have continued to take cost out of the business and have grown corporate TTV to help de-risk the overall cyclical nature of the business. With 2 rate cuts from the RBA, and more on the horizon, we think that the consumer can loosen the purse in FY26, with travel a likely beneficiary of this.

Telix Pharmaceuticals Ltd (ASX: TLX)

Another ASX 200 share that makes Bell Potter's list is growing radiopharmaceutical company Telix.

The broker believes that the company is well-placed for growth over the coming years. In fact, it is forecasting an earnings per share CAGR to 46% for the next couple of years.

In light of this, it thinks Telix's shares are attractively priced. It said:

TLX is building a vertically integrated radiopharmaceutical specialist company providing research, product development, isotope production, supply chain management and distribution in order to capture most of the margin in these highly valued assets for medical imaging and therapy. The company aims to initially dominate the urology space with a range of products for imaging, therapy and surgery. Valuations are attractive, with 12MF P/E now at 38x, supported by a 2yr EPS CAGR of 46%.